Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™)…

VERU INC. (VERU) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib

Event · Clinical / regulatory
Product
sabizabulin
Milestone
trial start
Indication
metastatic pancreatic cancer

Facts are quoted from the filing text and checked against it.

Original reporting
Published Sep 8, 2026, 12:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 11:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$VERU
Bullish
high confidence
Mentioned
$VERU
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VERUBullishHigh
01

Why it matters

The announcement positions Veru to address a high‑unmet need in KRAS‑driven pancreatic cancer, potentially expanding its market opportunity and attracting partnership interest.

02

Market read

First‑time disclosure of a new trial indication could trigger a short‑term rally in VERU shares and influence related oncology stocks.

03

What to watch

Potential competition from other KRAS inhibitors and the need for substantial funding for Phase 2.

Relevance 8/10Novelty 8/10Timing: today

Background

Veru Inc. (NASDAQ: VERU) is a clinical‑stage biopharma developing sabizabulin, an oral microtubule‑binding agent, and enobosarm for obesity.

Company-level read

Ticker impact

$VERUBullishHigh confidence
Context

Veru Inc. announced new preclinical data showing sabizabulin overcomes daraxonrasib resistance and plans a Phase 2 trial for KRAS‑driven pancreatic cancer.

Expected impact

Potential short‑term upside of 10‑15% if market reacts to the trial advancement.

Evidence & confidence

First disclosure of novel data and a clear development milestone for a late‑stage oncology asset; biotech stocks typically rally on such news.

Market effects

May lift sentiment for KRAS‑targeted oncology peers and related biotech pipelines.

US biotech sector could see modest gains.

Limited to investors focused on oncology drug development.

Counterpoint

Skeptics may argue preclinical data does not guarantee clinical success and could be overhyped.

Key entities

  • Veru Inc.

    Clinical‑stage biopharma developing sabizabulin.

  • Mitchell Steiner, M.D.

    CEO of Veru who provided the statement.

Related articles

$VERUMed

Veru presents data on enobosarm for obesity treatment

Veru Inc. (VERU) presented Phase 2b QUALITY study data at ObesityWeek 2026, showing enobosarm 3mg plus semaglutide helped patients aged 65+ with obesity gain lean mass and maintain physical function. The Phase 2b PLATEAU trial, with 239 patients, is ongoing, with interim data expected in Q1 2027. Veru has a clinical supply agreement with Novo Nordisk and a U.S. patent for the combination therapy.

$VERUMedAI 8/10

Veru executive to present obesity drug data at industry conference

Veru Inc. (VERU) will present obesity drug data at ObesityWeek 2026. Dr. Gary Barnette will discuss physical function in older patients using a GLP-1 receptor agonist from the QUALITY study. The company's Phase 2b PLATEAU trial has enrolled 239 patients, exceeding targets. Interim results are expected in Q1 2027, with final data in Q4 2027, according to the company.

$VERUMed

Why is Veru stock gaining today?

Veru Inc. (VERU) shares rose 1.8% after Oppenheimer reiterated its Outperform rating and $24 price target, citing confidence in enobosarm's Phase 2b trial results. The trial, fully enrolled with 239 patients, aims to show lean body mass preservation and fat loss benefits. Veru holds a U.S. patent for the enobosarm-semaglutide combination until 2044. The stock traded at $2.23, below its 52-week high of $7.33 but above its low of $2.05.

$VERUMed

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

VERU INC. (VERU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress — Phase 2b PLATEAU cl